• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by West Pharmaceutical Services Inc.

    6/26/24 4:10:18 PM ET
    $WST
    Medical/Dental Instruments
    Health Care
    Get the next $WST alert in real time by email
    11-K 1 wcm_form11-kx12312023.htm 11-K Document


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549
    FORM 11-K

    (Mark One)

    þ    ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    For the fiscal year ended December 31, 2023

    OR

    o    TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    For the transition period from ______ to _______


    Commission file number 1-8036
    A.    Full title of the plan and the address of the plan, if different from that of the issuer named below:


    WEST CONTRACT MANUFACTURING
    SAVINGS AND RETIREMENT PLAN


    B.    Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:

    WEST PHARMACEUTICAL SERVICES, INC.
    530 HERMAN O. WEST DRIVE
    EXTON, PA 19341-1147
    610-594-2900






    REQUIRED INFORMATION
    Items
    1 to 3.Not required; see Item 4 below.
    4.The following are furnished for the Plan:
    (a) The West Contract Manufacturing Savings and Retirement Plan is subject to the Employee Retirement Income Security Act of 1974 (“ERISA”), as amended, and is, therefore, filing Plan financial statements and schedules prepared in accordance with the financial reporting requirements of ERISA.
    (b) A written consent of the accountant.



























    WEST CONTRACT MANUFACTURING
    SAVINGS AND RETIREMENT PLAN

    FINANCIAL STATEMENTS AND SUPPLEMENTAL INFORMATION
    For the Years Ended December 31, 2023 and 2022



















    WEST CONTRACT MANUFACTURING
    SAVINGS AND RETIREMENT PLAN


    TABLE OF CONTENTS

    Page
    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
    1
    FINANCIAL STATEMENTS:
    Statements of Net Assets Available for Benefits
    3
    Statements of Changes in Net Assets Available for Benefits
    4
    Notes to Financial Statements
    5
    SUPPLEMENTAL INFORMATION*:
    Schedule H, Line 4i - Schedule of Assets (Held at End of Year)
    11
    SIGNATURE
    12
    EXHIBIT INDEX
    13
    * Other schedules required by 29 CFR 2520.103-10 of the Department of Labor’s Rules and Regulations for Reporting and Disclosure under ERISA have been omitted because they are not applicable.





    Table of Contents


    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


    To the Participants and the Administrator of
    West Contract Manufacturing Savings and Retirement Plan:

    Opinion on the Financial Statements

    We have audited the accompanying statements of net assets available for benefits of the West Contract Manufacturing Savings and Retirement Plan (the “Plan”) as of December 31, 2023 and 2022, and the related statements of changes in net assets available for benefits for the years then ended, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2023 and 2022, and the changes in net assets available for benefits for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

    Basis for Opinion

    These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

    We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.

    Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.


    1

    Table of Contents


    Supplemental Information

    The supplemental information in the accompanying schedule H line 4i schedule of assets (held at end of year) as of December 31, 2023, has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental information is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.


    /s/ Fischer Cunnane & Associates Ltd

    We have served as the Plan’s auditor since 2009.

    West Chester, Pennsylvania
    June 26, 2024

    2

    Table of Contents


    WEST CONTRACT MANUFACTURING
    SAVINGS AND RETIREMENT PLAN
    STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS
    AS OF DECEMBER 31, 2023 AND 2022



    20232022
    Assets:
    Investments:
    Investments at fair value (Note D)$8,498,809 $6,760,356 
    Plan interest in Master Trust (Note C)— 310,388 
    Total investments8,498,809 7,070,744 
    Receivables:
    Employer contributions227,030 227,746 
    Notes receivable from participants230,514 226,044 
    Total receivables457,544 453,790 
    Total assets8,956,353 7,524,534 
    Liabilities:
    Excess contributions payable
    15,848 16,031 
    Net assets available for benefits$8,940,505 $7,508,503 




















    The accompanying Notes are an integral part of these statements.

    3

    Table of Contents


    WEST CONTRACT MANUFACTURING
    SAVINGS AND RETIREMENT PLAN
    STATEMENTS OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS
    FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022



    20232022
    Additions:
    Investment income (loss):
    Interest and dividend income$272,496 $360,041 
    Net appreciation (depreciation) in fair value of investments957,942 (1,860,355)
    Plan interest in Master Trust net investment income (loss)174,324 (366,373)
    Net investment income (loss)1,404,762 (1,866,687)
    Interest income on notes receivable from participants12,266 10,115 
    Contributions:
    Employer455,046 451,474 
    Participant453,927 460,350 
    Total contributions908,973 911,824 
    Total additions (reduction)2,326,001 (944,748)
    Deductions:
    Benefits paid886,263 897,742 
    Plan expenses7,736 7,321 
    Total deductions893,999 905,063 
    Net increase (decrease)1,432,002 (1,849,811)
    Net assets available for plan benefits:
    Beginning of the year7,508,503 9,358,314 
    End of the year$8,940,505 $7,508,503 










    The accompanying Notes are an integral part of these statements.

    4

    Table of Contents




    WEST CONTRACT MANUFACTURING
    SAVINGS AND RETIREMENT PLAN
    NOTES TO FINANCIAL STATEMENTS
    FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022
    NOTE A - Description of Plan

    The following description of the West Contract Manufacturing Savings and Retirement Plan (the “Plan”) provides only general information. Participants should refer to the Plan document for a more complete description of the Plan’s current provisions.

    General
    The Plan is a defined contribution plan that was established January 1, 1993, and subsequently amended. The Plan was most recently amended effective January 1, 2022. Full-time employees of West Contract Manufacturing LLC (the “Employer”), a subsidiary of West Pharmaceutical Services, Inc. (the "Company"), who are at least eighteen years of age are immediately eligible to participate in the Plan. The Plan is subject to the provisions of the ERISA, as amended, and is designed to comply with Section 1081.01(d) of the Puerto Rico Internal Revenue Code of 2011 (the “Code”), as amended.

    Master Trust
    Effective August 1, 2023, recordkeeping services for the Plan transferred from Vanguard Fiduciary Trust Company ("VFTC"), who held the Master Trust investments effective January 3, 2011, to Fidelity Management Trust Company (“FMTC”). The sole investment in the Master Trust was common stock of the Company (the “West Stock Fund”). As part of the transfer, the West Pharmaceutical Services, Inc. Master Trust for Defined Contribution Plans, which included the West Pharmaceutical Services Inc. 401(k) Plan, was terminated and the West Contract Manufacturing Savings and Retirement Plan Trust, a single plan trust, was adopted effective August 1, 2023. References to the "Trust" within this filing refer to the West Pharmaceutical Services, Inc. Master Trust for Defined Contribution Plans through July 31, 2023 and the West Contract Manufacturing Savings and Retirement Plan Trust on and after August 1, 2023. With the transfer to FMTC, the West Stock Fund moved from a unitized stock fund to actual stock held in participant accounts. See Note C for more information regarding the Master Trust.

    Automatic Enrollment and Escalation
    Employees hired on January 1, 2020 or later are automatically enrolled in the Plan 30 days following their date of hire at a pre-tax contribution rate of 3% of eligible compensation. Furthermore, this rate will increase by 1% on April 1st every year until a 10% contribution deferral rate is reached. Employees may choose to decline participation or escalation by contacting FMTC, recordkeeper for the Plan.

    Employee Contributions
    Eligible employees may contribute up to 50% of pre-tax annual compensation and 10% of after-tax annual compensation, provided such contributions do not exceed the limits of the Code. Participants may also contribute amounts representing distributions from other qualified defined benefit or defined contribution plans.

    Company Matching Contributions
    The Company matches 100% of the first 3% of compensation that a participant contributes to the Plan and 50% of the next 2% of compensation contributed to the Plan.

    Non-Elective Company Contributions
    Beginning in 2019, all employees were eligible to receive a Non-Elective Company Contribution to the Plan equal to 3% of the employee’s compensation. Employees must be employed on December 31 or have terminated employment during the year due to death, total and permanent disability, or in connection with an involuntary reduction in force such as a restructuring, reorganization, plant closure, or mass layoff or have reached age 55 with at least 10 years of service to be eligible for the annual Non-Elective Company Contribution.


    5

    Table of Contents




    WEST CONTRACT MANUFACTURING
    SAVINGS AND RETIREMENT PLAN
    NOTES TO FINANCIAL STATEMENTS
    FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022
    The Non-Elective Company Contribution is made annually and will be allocated to participant accounts no later than the March 15 that follows the end of the previous calendar year.

    Investments
    The Plan offers mutual funds and the West Stock Fund as investment options for participants. The Company’s Investment Committee periodically reviews, and may make changes to, the investment alternatives available.

    Participants may change or transfer their investment options at any time. Company matching contributions and Non-Elective Company Contributions are invested according to the investment allocations made for participant contributions.

    Participant Accounts
    Individual accounts are maintained for each Plan participant. Each account is self-directed and is credited with the participant’s contribution, the Company’s Matching Contribution and any applicable Non-Elective Company Contributions, and an allocation of Plan earnings (losses). Participant accounts are charged with certain administrative expenses. Allocations are based on participant earnings or account balances, as defined. The benefit to which a participant is entitled is the benefit that can be provided from the participant’s vested account.

    Vesting
    Participants are immediately vested in their contributions and Company Matching Contributions, plus earnings thereon. Participants become vested in the Non-Elective Company Contributions after completing three years of service with the Company. All contributions are 100% vested when a participant reaches age 65, dies, becomes totally and permanently disabled or upon plan termination.

    Notes Receivable from Participants
    Participants may borrow from their fund accounts a maximum amount equal to the lesser of $50,000 or 50% of the vested portion of their account balances. The loans are secured by the balance in the participant’s account. Loan terms generally range from one to five years, except for loans to purchase a principal residence which may be repaid over fifteen years, and bear interest at the prevailing interest rate determined by the Plan Administrator on the date the loan is made. At December 31, 2023, the interest rate on outstanding loans ranged from 4.25% to 9.50%. At December 31, 2022, the interest rate on outstanding loans ranged from 4.25% to 7.25%. Principal and interest are paid ratably through payroll deductions.

    Benefits
    Benefits are payable upon termination of a participant’s employment, or termination of service due to death, disability or retirement. Participants may make annual in-service withdrawals in accordance with the provisions outlined in the Plan document. Generally, any benefit due shall be paid as soon as administratively feasible.

    NOTE B - Summary of Significant Accounting Policies

    Basis of Accounting
    The accompanying financial statements of the Plan are prepared using the accrual basis of accounting.

    Use of Estimates
    The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying footnotes. Actual results could differ from these estimates.


    6

    Table of Contents




    WEST CONTRACT MANUFACTURING
    SAVINGS AND RETIREMENT PLAN
    NOTES TO FINANCIAL STATEMENTS
    FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022
    Valuation of Investments and Income Recognition
    The Plan’s investments are stated at fair value. See Note D for discussion of fair value measurements, with the exception of the Master Trust, which is discussed in Note C. Purchases and sales of investments are recorded on a trade-date basis. The Plan presents in its statements of changes in net assets available for benefits the net appreciation (depreciation) in the fair value of its investments, which consists of both realized and unrealized gains and losses.

    Dividend income is recorded on the ex-dividend date. Capital gain distributions are included in dividend income. Interest income is accrued when earned.

    Payment of Benefits
    Benefits are recorded when paid. Delinquent notes receivable from participants are treated as distributions based upon the terms of the Plan document.

    Plan Expenses
    Administrative expenses of the Plan are paid jointly by participants and the Employer.

    NOTE C - Master Trust

    As mentioned in Note A, a portion of the Plan’s investments were held in a Master Trust, commingled with assets of another Company-sponsored retirement plan. The sole investment in the Master Trust was the West Stock Fund.

    The total fair value of the Master Trust’s investment in the West Stock Fund, as of December 31, 2023 and 2022, was $0 and $50,380,941, respectively. The West Stock Fund was valued at the year-end unit closing price, which is comprised of the quoted market price of the Company stock plus an uninvested cash portion, which is considered a Level 1 fair value measurement.

    Effective January 1, 2022, the Plan was amended to freeze the investment of contributions and accounts in the common stock of the Plan sponsor.

    The changes in net assets for the Master Trust for the years ended December 31 are as follows:
    20232022
    Dividends
    $77,919 $166,548 
    Net appreciation (depreciation) in fair value of common stock27,123,780 (53,922,978)
    Net investment income (loss)27,201,699 (53,756,430)
    Net deductions and interfund transfers(8,573,786)(10,864,695)
    Net transfers to FMTC(69,008,854)— 
    Decrease in net assets(50,380,941)(64,621,125)
    Net assets:
        Beginning of year50,380,941 115,002,066 
        End of year$— $50,380,941 


    7

    Table of Contents




    WEST CONTRACT MANUFACTURING
    SAVINGS AND RETIREMENT PLAN
    NOTES TO FINANCIAL STATEMENTS
    FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022
    The Plan’s share of the Master Trust’s net assets and investment activities was based upon the total of each individual participant’s share of the Master Trust. The Plan’s interest in the net assets of the Master Trust was 0.00% and 0.62% as of December 31, 2023 and 2022, respectively.

    The following tables summarize the Plan's investments in the Master Trust for the years ended December 31:

    Master Trust BalancePlan's Interest in Master Trust Balance
    20232023
    Common Stock$— $— 
    Total investments at fair value$— $— 

    Master Trust BalancePlan's Interest in Master Trust Balance
    20222022
    Common Stock$50,380,941 $310,388 
    Total investments at fair value$50,380,941 $310,388 


    NOTE D - Fair Value Measurements

    Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

    The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:

    Level 1:    Unadjusted quoted prices in active markets for identical assets or liabilities.

    Level 2:    Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

    Level 3:    Unobservable inputs that reflect the reporting entity’s own assumptions.


    8

    Table of Contents




    WEST CONTRACT MANUFACTURING
    SAVINGS AND RETIREMENT PLAN
    NOTES TO FINANCIAL STATEMENTS
    FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022
    The following tables summarize the Plan’s investments, excluding the Master Trust, that are measured at fair value on a recurring basis:
    Balance at
    Basis of Fair Value MeasurementsDecember 31,
    Level 1Level 2Level 32023
    Mutual funds$8,047,052 $— $— $8,047,052 
    West Pharmaceutical Services, Inc. Common Stock451,757 — — 451,757 
    Total Investments at fair value$8,498,809 $— $— $8,498,809 

    Balance at
    Basis of Fair Value MeasurementsDecember 31,
    Level 1Level 2Level 32022
    Mutual funds$6,760,356 $— $— $6,760,356 
    Total Investments at fair value$6,760,356 $— $— $6,760,356 

    The valuation methodologies used for assets measured at fair value are as follows:

    Mutual funds and common stock: The fair values of mutual fund investments and common stock are determined by obtaining quoted prices on nationally recognized securities exchanges.

    NOTE E - Risks and Uncertainties

    The Plan provides for various investment options. Investment securities are exposed to various risks, such as interest rate, market and credit. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the value of investment securities, it is at least reasonably possible that changes in risks in the near term would materially affect participants’ account balances and the amounts reported in the statements of net assets available for benefits and the statements of changes in net assets available for benefits.

    NOTE F - Related Party and Party-in-Interest Transactions

    The Plan invested in the West Stock Fund, as defined by the Plan, through July 31, 2023. As of August 1, 2023, the West Stock Fund moved from a unitized stock fund to actual stock held in participant accounts. Therefore, these transactions qualify as party-in-interest transactions, which are exempt from the prohibited transaction rules. In addition, loans to participants qualify as party-in-interest transactions.

    NOTE G - Plan Termination

    Although it has not expressed any intent to do so, the Company has the right under the Plan to discontinue its contributions at any time and to terminate the Plan subject to the provisions of ERISA. In the event of termination of the Plan, participants’ accounts will be distributed in accordance with the provisions of the Plan.


    9

    Table of Contents




    WEST CONTRACT MANUFACTURING
    SAVINGS AND RETIREMENT PLAN
    NOTES TO FINANCIAL STATEMENTS
    FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022
    NOTE H - Tax Status

    The Plan obtained its latest determination letter on January 23, 2018, in which the Puerto Rico Department of Treasury (“Treasury”) stated that the Plan, as then designed, was in compliance with the applicable requirements of the Code. The Plan has been amended since requesting the determination letter. However, the Plan Administrator and the Plan’s tax counsel believe that the Plan is currently designed and being operated in compliance with the applicable requirements of the Code. Therefore, no provision for income taxes has been included in the Plan’s financial statements.

    U.S. GAAP requires Plan management to evaluate tax positions taken by the Plan and recognize a tax liability (or asset) if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by the Internal Revenue Service or Treasury. The Plan Administrator has analyzed the tax positions taken by the Plan, and has concluded that, as of December 31, 2023, there were no uncertain positions taken or expected to be taken that require recognition or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress. The Plan Administrator believes the Plan is no longer subject to income tax examinations prior to 2019.

    NOTE I - Subsequent Events

    The Plan has evaluated, for consideration of recognition or disclosure, subsequent events that have occurred through the date of issuance, June 26, 2024, and has determined that no significant events occurred after December 31, 2023 but prior to the issuance of these financial statements, that would have a material impact on its financial statements.

    10

    Table of Contents


    WEST CONTRACT MANUFACTURING
    SAVINGS AND RETIREMENT PLAN
    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)
    AS OF DECEMBER 31, 2023
    PLAN EIN: 86-0640193
    PLAN NUMBER: 001
    (a)(b) Identity of issue, borrower, lessor, or similar party(c) Description of investment including maturity date, rate of interest, collateral, par, or maturity value(d) Cost(e) Current Value
    American Funds EuroPacific Growth Fund Class R6Mutual Fund**$538,594 
    MFS Global Equity Fund Class R6Mutual Fund**87,919 
    PIMCO Inflation Response Multi-Asset Fund Institutional ClassMutual Fund**13,413 
    Vanguard Cash Reserve Federal MM FundMutual Fund**325,654 
    Vanguard Diversified Equity FundMutual Fund**1,740,275 
    Vanguard Target Retirement 2020 FundMutual Fund**963,270 
    Vanguard Target Retirement 2025 FundMutual Fund**197,565 
    Vanguard Target Retirement 2030 FundMutual Fund**268,105 
    Vanguard Target Retirement 2035 FundMutual Fund**240,600 
    Vanguard Target Retirement 2040 FundMutual Fund**152,730 
    Vanguard Target Retirement 2045 FundMutual Fund**210,813 
    Vanguard Target Retirement 2050 FundMutual Fund**114,655 
    Vanguard Target Retirement 2055 FundMutual Fund**66,761 
    Vanguard Target Retirement 2060 FundMutual Fund**19,758 
    Vanguard Target Retirement 2065 FundMutual Fund**19,964 
    DoubleLine Core Plus Fixed Income FundMutual Fund**111,230 
    Vanguard Target Retirement Income FundMutual Fund**395,882 
    Vanguard Total Bond Market Index Fund Institutional SharesMutual Fund**630,666 
    Vanguard Total International Stock Index Fund Admiral SharesMutual Fund**110,958 
    Vanguard Total Stock Market Index Fund Institutional SharesMutual Fund**1,747,872 
    Vanguard Total World Stock Index Fund Admiral SharesMutual Fund**90,368 
    *West Pharmaceutical Services, Inc. Common StockCommon Stock**451,757 
    *Participant Loans4.25% - 9.50%$0230,514 
    $8,729,323 
    *Party-in-interest
    **Cost has been omitted, as investment is participant-directed.


    11

    Table of Contents




    SIGNATURE

    The Plan. Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.



    WEST CONTRACT MANUFACTURING SAVINGS AND RETIREMENT PLAN


    By: /s/ Annette F. Favorite
    Annette F. Favorite
    Plan Administrator



    Date:  June 26, 2024

    12

    Table of Contents


    EXHIBIT INDEX
    Exhibit
    Number
    Description
    23.1
    Consent of Independent Registered Public Accounting Firm


    13
    Get the next $WST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WST

    DatePrice TargetRatingAnalyst
    12/2/2025$285.00Equal-Weight
    Morgan Stanley
    9/15/2025$311.00Buy
    Rothschild & Co Redburn
    6/24/2025$245.00Equal Weight
    Barclays
    3/18/2025$275.00Outperform
    Evercore ISI
    2/14/2025$250.00Hold → Buy
    Deutsche Bank
    1/8/2025$400.00Buy
    Citigroup
    12/13/2024Peer Perform
    Wolfe Research
    12/12/2024$350.00 → $390.00Neutral → Buy
    UBS
    More analyst ratings

    $WST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    West to Host Fourth-Quarter and Full-Year 2025 Conference Call

    EXTON, Pa., Jan. 29, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 12, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registe

    1/29/26 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West Synchrony™ S1 Prefillable Syringe System Commercially Available at Pharmapack

    Showcasing Leadership in Drug Delivery Solutions and Approaches to Combination Products EXTON, Pa., Jan. 20, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced participation at Pharmapack 2026 in Paris, France to showcase its leadership and expertise on industry challenges and trends in packaging and containment. This event marks the global commercial availability of West Synchrony™ S1 prefillable syringe (PFS) system. West Synchrony S1 PFS system provides a broad product po

    1/20/26 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie

    EXTON, Pa., Jan. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that the company has reached a definitive agreement to sell all manufacturing and supply rights for SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie (NYSE:ABBV) for total consideration of $112.5 million at close, subject to working capital and other adjustments. The definitive agreement, which is subject to certain closing conditions, is expected to close in mid-2026. Wes

    1/12/26 6:00:00 AM ET
    $ABBV
    $WST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $WST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Haugen Janet Brutschea

    4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

    1/5/26 12:37:29 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by SVP, GC & Corporate Secretary Finch Norman D. Jr.

    4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

    12/10/25 10:33:41 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Finch Norman D. Jr.

    3 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

    12/10/25 10:32:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by West Pharmaceutical Services Inc.

    SCHEDULE 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

    10/31/25 11:41:37 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by West Pharmaceutical Services Inc.

    10-Q - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

    10/23/25 4:14:52 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

    10/23/25 7:15:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley initiated coverage on West Pharm with a new price target

    Morgan Stanley initiated coverage of West Pharm with a rating of Equal-Weight and set a new price target of $285.00

    12/2/25 8:36:52 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    Rothschild & Co Redburn initiated coverage on West Pharm with a new price target

    Rothschild & Co Redburn initiated coverage of West Pharm with a rating of Buy and set a new price target of $311.00

    9/15/25 8:12:22 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    Barclays initiated coverage on West Pharm with a new price target

    Barclays initiated coverage of West Pharm with a rating of Equal Weight and set a new price target of $245.00

    6/24/25 8:11:45 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Financials

    Live finance-specific insights

    View All

    West to Host Fourth-Quarter and Full-Year 2025 Conference Call

    EXTON, Pa., Jan. 29, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 12, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registe

    1/29/26 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West Declares Quarterly Dividend

    EXTON, Pa., Dec. 10, 2025 /PRNewswire/ -- On December 9, 2025, the board of directors of West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, declared its regular quarterly dividend of $0.22 per share on the Company's common stock. The dividend is payable on February 4, 2026, to shareholders of record on January 28, 2026. About WestWest Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug devel

    12/10/25 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West Reports Third-Quarter 2025 Results

    - Delivered solid growth across Proprietary Products and Contract Manufacturing Segments - - Achieved double-digit growth in HVP Components -- Strengthened executive leadership team, including recently appointed CFO Robert McMahon -- Increases Full-Year 2025 Revenue and EPS Guidance - EXTON, Pa., Oct. 23, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the third quarter of 2025. Third-Quarter Summary (comparisons to prior-year period)

    10/23/25 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

    SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

    2/13/24 5:17:38 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

    SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

    2/14/23 12:37:59 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

    SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

    2/10/22 8:47:14 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Leadership Updates

    Live Leadership Updates

    View All

    West Welcomes Robert McMahon as Incoming Chief Financial Officer

    EXTON, Pa., July 21, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced the appointment of Robert McMahon as the company's new Chief Financial Officer (CFO), effective August 4, 2025. Mr. McMahon will succeed Bernard Birkett, CFO, who announced his intention to retire earlier this year. Mr. Birkett will assume the role of Senior Advisor to the CEO through the end of the year to ensure a seamless transition.   "Bob is an accomplished CFO and business executive within the

    7/21/25 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    Sotera Health Appoints Karen Flynn to Board of Directors

    CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal

    11/13/23 7:00:14 AM ET
    $CTLT
    $QTRX
    $SHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    West Announces Executive Leadership Appointments

    EXTON, Pa., May 12, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today the appointment of West's Chief Financial Officer (CFO) Bernard J. Birkett to a newly combined position of Chief Financial and Operations Officer. In this expanded role, Mr. Birkett will lead our Global Operations and Global Supply Chain. The Company's Senior Vice President, Chief Global Operations and Supply Chain Officer, David Montecalvo has announced his resignation to pursue other interests with a departure of July 2022 to ensure a seamless transition.

    5/12/22 4:30:00 PM ET
    $WST
    Medical/Dental Instruments
    Health Care